Cloudbreak Pharma (HKSE:02592) Cash Flow for Dividends: HK$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02592 Cloudbreak Pharma Inc HKSE:02592
11 GF Score
Price HK$1.20
! 2 Warning Signs
View Full Analysis

What is Cloudbreak Pharma Cash Flow for Dividends?

Cloudbreak Pharma HKSE:02592 -1.64% 11 Cash Flow for Dividends is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Cloudbreak Pharma's cash flow for dividends for the six months ended in Dec. 2025 was HK$0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Cloudbreak Pharma Cash Flow for Dividends Related Terms

Cloudbreak Pharma Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Cloudbreak Pharma's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cloudbreak Pharma Cash Flow for Dividends Chart

Cloudbreak Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
0.00 0.00 0.00 0.00

Cloudbreak Pharma Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
HKSE:02592
11GF Score
Cloudbreak Pharma Inc HKSE:02592
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cloudbreak Pharma Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of HK$0.00 Mil mean?
Cloudbreak Pharma (HKSE:02592) has a Cash Flow for Dividends of HK$0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Cloudbreak Pharma and its competitors.
Is Cloudbreak Pharma's Cash Flow for Dividends too high?
Cloudbreak Pharma's current Cash Flow for Dividends is HK$0.00 Mil. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Cash Flow for Dividends compare to VRTX and REGN?
Cloudbreak Pharma's Cash Flow for Dividends of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Cash Flow for Dividends is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Cash Flow for Dividends of HK$0.00 Mil. The current Cash Flow for Dividends is HK$0.00 Mil. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Cash Flow for Dividends is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cloudbreak Pharma Business Description

Address 8921 Research Drive, Irvine, CA, USA, 92618
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score

Get the complete analysis for HKSE:02592

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.20
Price